Programme Day 2

08.15 - 09.15

Venous Thrombosis
Oral Communication
Hall: Auditorium

08.15 – 08.30: Validation of a profile of 6 miRNAs as predictor of early incidental post-surgical pulmonary embolism in glioma patients by Álvaro Fernández-Pardo, Spain

08.30 – 08.45: The role of stroke as a trigger for incident venous thromboembolism: results from a case-crossover study by Vania Morelli, Norway

08.45 – 09.00: Association of Neutrophil Extracellular Traps Markers and Venous Thromboembolism. Results of RETROVE Project by Marc Arus, Spain

09.00 – 09.15: B lymphocytes and endothelial dysfunction promote DVT by Catherine Lemarie, Canada

Platelets and Neutrophils
Oral Communication
Hall: Callelongue

08.15 – 08.30: HLA variant rs6903608 is associated with disease onset and relapse of immune-mediated thrombotic thrombocytopenic purpura by Ilaria Mancini, Italy

08.30 – 08.45: Neutrophils prothrombotic characteristics during myeloproliferative neoplasms by Chloé James, France

08.45 – 09.00: Caplacizumab for acquired thrombotic thrombocytopenic purpura – results of the phase 3 HERCULES study by Flora Peyvandi, Belgium

09.00 – 09.15: Neutrophil-endothelial cell interactions determine the regulation of neutrophil activities by platelets by Soumaya Jadoui, France

Inflammation
Oral Communication
Hall: Endoume 1

 

08.15 – 08.30: Complement Activation Assessed by Terminal Complement Complex and Future Risk of Venous Thromboembolism by Ina Isabella Høiland, Norway

08.30 – 08.45: Detection of different fibrinolysis patterns of plasminogen mutant proteins in patients with ligneous conjunctivitis associated to inherited plasminogen deficiency: impact on clinical outcome by Marie-Charlotte Bourrienne, France

08.45 – 09.00: The differential role of platelets and fibrin in adhesion on inflamed and damaged valves in a new mouse model of early staphylococcus aureus endocarditis by Severien Meyers, Belgium

09.00 – 09.15 : Neutrophil extracellular traps are associated with the pathogenesis of diffuse intra-alveolar hemorrhage in murine lupus by Pierre-André Jarrot, France

Von Willebrand Factor
Oral Communication
Hall: Endoume 2

08.15 – 08.30    Von Willebrand factor deficiency does not influence angiotensin II-induced abdominal aortic aneurysm formation in mice by Irina Portier, Belgium

08.30 – 08.45    HNA-3a Expressed by CTL-2 is a Crucial Epitope for Neutrophil Adhesion and Activation on VWF by Gaia Zirka, France

08.45 – 09.00    The role of von Willebrand factor in experimental malaria-associated acute respiratory distress syndrome by Sirima Kraisin, Belgium

09.00 – 09.15    The VWF-GPIb interaction mediates thrombo-inflammation in experimental stroke via recruitment of monocytes, neutrophils and T-cells to the brain by Frederik Denorme, Belgium

09.15 - 09.30

Short break

09.30 - 10.30

Novel Treatments
Oral Communications
Hall: Auditorium

 

09.30 – 09.45: Cleavage of anti-PF4/H IgG antibodies by IdeS, and potential benefit in the treatment of heparin-induced thrombocytopenia by Jerome Rollin, France

09.45 – 10.00: Generation of llama-derived single-domain antibodies directed against anticoagulant protein S by François Saller, France

10.00 – 10.15: Factor VIII activity and anti-FVIII inhibitor titer determination on patients treated with Hemlibra® (emicizumab): which FVIII assay used?  by Corentin Achard, France

10.15 – 10.30: Search for antithrombin chemical inhibitors as an oral treatment for Hemophilia by Elsa Bianchini, France

Oral Anticoagulation
Oral Communications
Hall: Callelongue

09.30 – 09.45: Vitamin K antagonist (VKA) versus direct oral anticoagulants in patients with currently well controlled VKA for non-valvular atrial fibrillation: a randomised controlled pilot trial by Jasper van Miert, The Netherlands

09.45 – 10.00: Perioperative management in patients using vitamin K antagonists: a cohort study by Louise Burggraaf, The Netherlands

10.00 – 10.15: Neutralisation of non-vitamin K anticoagulants by α2Macroglobulin-trapped factor Xa by Georges Jourdi, France 

10.15 – 10.30: Targeted Substitution at the S4 Subsite of Human Factor X Infers Resistance to the Direct Factor Xa Inhibitors by Mark Schreuder, The Netherlands

ADAMTS13
Oral Communications
Hall: Endoume 1

 

09.30 – 09.45: Inhibiting ADAMTS13 activity prevents the loss of high molecular weight von Willebrand factor multimers in in vitro left ventricular assist devices by Shannen Deconinck, Belgium

09.45 – 10.00: Crystal structure and allosteric activation of ADAMTS13 by James Crawley, United Kingdom

10.00 – 10.15: Open ADAMTS13 conformation in immune-mediated thrombotic thrombocytopenic purpura is induced by anti-ADAMTS13 autoantibodies and corresponds with an ongoing ADAMTS13 pathology by Elien Roose, Belgium

10.15 – 10.30: ADAMTS13 peptide presentation in acquired thrombotic thrombocytopenic purpura by Johana Hrdinova, The Netherlands

Cancer and Thrombosis
Oral Communications
Hall: Endoume 2

09.30 – 09.45: Biological pro-coagulant and pro-inflammatory effect of interferon alpha in myeloproliferative neoplasms by Nadine Ajzenberg, France

09.45 – 10.00: Analysis of microvesicle-mediated thrombosis in CRISPR/CAS9-mediated tissue factor knockout breast cancer cells by Araci M R Rondon, The Netherlands

10.00 – 10.15: Paradoxical roles of platelets in colorectal cancer by Léa Plantureux, France

10.15 – 10.30: Increased incidence of cancer in the follow-up of obstetric antiphospholipid syndrome: the NOHA-K observational study by Jean-Christophe Gris, France

10.30 - 11.00

Coffee break & poster viewing

11.00 - 11.30

State of the Art
Prediction of thrombosis
Suzanne Cannegieter
The Netherlands
Hall: Auditorium

State of the Art
Biochemical basis non-replacement therapy – Peter Lenting
France
Hall: Callelongue

11.30 - 12.00

State of the Art
Different treatment for different clots
Steffen Massberg
Germany
Hall: Auditorium

12.00 - 12.15

Short break

12.15 - 13.15

Special symposium (not part of main CME/CPD programme)
Hall: Auditorium

Special symposium (not part of main CME/CPD programme)
Hall: Callelongue

Special symposium (not part of main CME/CPD programme)
Hall: Endoume 1

Special symposium (not part of main CME/CPD programme)
Hall: Endoume 2

13.15 - 13.30

Short break

13.30 - 14.30

Plenary lecture – NETs: The nuclear threat of inflammation – Denisa Wagner, United States of America
Hall: Auditorium

14.30 - 15.15

Renal Disease and Thrombosis
Oral communication
Hall: Auditorium

14.30 – 14.45: Frequency and prognostic impact of acute kidney injury in patients with pulmonary embolism. Data from the RIETE registry by Martin Murgier, France

14.45 – 15.00: Comparison of two different prophylactic regimens for the prevention of arteriovenous fistula thrombosis in patients with end stage renal disease by Gorana Mitic, Sebia

15.00 – 15.15: Aryl hydrocarbon receptor-related mechanisms of endothelial tissue factor induction by the uremic toxin indole-3 acetic acid by Tawfik Addi, Algeria

NETs
Oral communication
Hall: Callelongue

 

14.30 – 14.45: MiR-146a contributes to arterial thrombosis development through regulating neutrophils extracellular traps (NETs) formation by Ana Belén Arroyo Rodríguez. Spain

14.45 – 15.00: Novel platelet-neutrophil interaction via activated αIIbß3 mediates NETosis under flow by James Crawley, United Kingdom

15.00 – 15.15: Inhibition of protein Z-dependent protease inhibitor by neutrophil elastase may promote procoagulant activity of neutrophil extracellular traps by Elsa Bianchini, France

Platelets
Oral communication
Hall: Endoume 1

 

14.30 – 14.45: Platelet lamellipodia formation is not required for thrombus formation and stability by Yvonne Schurr, Germany

14.45 – 15.00: Critical role of platelets during lung fibrosis by Yacine Boulaftali, France

15.00 – 15.15: Effect of platelet-specific protein S depletion in murine haemostasis by Pablo García de Frutos, Spain

Acquired Platelet Impairment
Oral communication
Hall: Endoume 2

14.30 – 14.45: Shedding of platelet adhesion receptors GpIb and GpVI under continuous-flow mechanical circulatory support by Antoine Rauch, France

14.45 – 15.00: Rivaroxaban and Apixaban Reduce Thrombin-dependent Platelet Aggregation by Juraj Sokol, Slovakia

15.00 – 15.15: Platelet function during extracorporeal membrane oxygenation (ECMO) in adult patients by Camilla Mains Balle, Denmark

15.15 - 15.45

Coffee break & poster viewing

15.45 - 17.00

Thrombosis; Novel antithrombotic treatments
Invited integrated symposium
Hall: Auditorium

 

 

15.45 – 16.05: Novel ways to inhibit TAFIa in thrombotic disorders by Michael A. Grosso, United States of America

16.05 – 16.25: Targeting The Intrinsic Coagulation Pathway with Antisense Technology by Brett Monia, United States of America

16.25 – 16.45: Adherence and persistence on DOACs by Willem Lijfering, The Netherlands

16.45 – 17.00: Q&A

Platelets: New antiplatelet agents
Invited integrated symposium
Hall: Callelongue

 

 

15.45 – 16.05: Towards a new approach for inhibiting P2Y12 receptors by Markus Riederer, Switzerland

16.05 – 16.25: GPVI and the development of a MoAb by Martine Jandrot-Perrus, France

16.25 – 16.45: Potential new antithrombotic agents targeting platelet intracellular proteins by Jonathan Gibbins, United Kingdom

16.45 – 17.00: Q&A

Bleeding: Hemophilia treatment: the next step
Invited integrated symposium
Hall: Endoume 1

 

15.45 – 16.00: Safety of novel non replacement therapies in combination with FVIII or bypassing agents? By Johannes Oldenburg, Germany

16.00 – 16.15: Opportunities and challenges in clinical trial designs for haemophilia gene therapies by Benjamin Kim, United States of America

16.15 – 16.30: Preclinical efficacy and safety of SerpinPC by Jim Huntington, United Kingdom

16.30 – 16.45: European patient organization (EHC) Patients position with replacement and non replacement therapies in Hemophilia. What they want to know? by Brian O’Mahony, Ireland

16.45 – 17.00: Q&A

Assays: New treatments, new assays
Invited integrated symposium
Hall: Endoume 2

 

 

15.45 – 16.00: New drugs new assays by Cristina Novembrini, Italy 

16.00 – 16.15: Detection of lupus anticoagulants in DOAC -Treated patients by Gary Moore, United Kingdom

16.15 -16.30: Measurements/platelet reactivity testing by Yves Gruel, France

16.30 – 16.45: ADAMTS13: a fast new assay for diagnosis of acute TTP by Maribel Mirabet, Spain

16.45 – 17.00: Q&A

17.00 - 18.30

Poster reception & poster viewing

 

17.30 - 18.30

Poster session – Vessel Wall

17.30 – 17.40Board No 1: NETs can help to estimate the thrombotic risk in biliopancreatic cancer patients at diagnosis by Álvaro Fernández-Pardo, Spain

17.40 – 17.50Board No 2: Plasma levels of proteins with endothelium enriched expression and risk of venous thromboembolism – a nested case-control study by Maria Jesus Iglesias, Sweden

17.50 – 18.00Board No 3: The role of coagulation factors and platelets on microvascular integrity in atrial fibrillation: impact of NOACs by Sophie Dolleman, The Netherlands

18.00 – 18.10Board No 4: Endothelial cells and neutrophils dependent, platelets and NETs-independent are involved in activation of the blood coagulation cascade leading to thrombus formation following a laser-induced injury by Estelle Carminita, France

18.10 – 18.20Board No 5: Frequency and characteristics of atrial appendages thrombi in atrial fibrillation patients treated with warfarin or dabigatran by Oksana Kalashnykova, Ukraine

18.20 – 18.30Board No 6: Direct inhibition of factor Xa by rivaroxaban is cardioprotective in rats via a cytoprotective effect on cardiomyocytes by Sophie Guillou, France

Poster session – Bleeding 1

17.30 – 17.40: Board No 7: The Pharmacokinetic Properties Of Factor IX Can Be Improved Using Genetic Fusion To Factor XIII-B Subunit by Sandra Le Quellec, France

17.40 – 17.50: Board No 8: Emicizumab prophylaxis administered once-weekly or every two weeks provides effective bleed prevention in persons with hemophilia A (PwHA) without inhibitors – Results from the phase III HAVEN 3 study by Claude Négrier, France

17.50 – 18.00: Board No 9: Revised pharmacokinetic of Benefix by Brigitte Tardy, France

18.00 – 18.10: Board No 10: Multicenter pharmacokinetic evaluation of RFVIII-FC (elocta®) in ‘real life’ and comparison with non-extended half-life FVIII concentrates by Claire Pouplard, France

18.10 – 18.20: Board No 11: Efficacy and safety of hFVIII/VWF concentrate (Voncento®) in patients with von Willebrand disease (VWD) requiring surgical procedures: the French experience by Lucia Rugeri, France

18.20 – 18.30: Board No 12: Management and outcome of bleeding complications in patients treated with direct oral anticoagulants by Roisin Bavalia, The Netherlands

Poster session – Bleeding 2

17.30 – 17.40Board No 13: Inhibiting ADAMTS13 in a preclinical ovine left ventricular assist device model does not rescue the loss of high molecular weight von Willebrand factor multimers by Shannen Deconinck, Belgium

17.40 – 17.50: Board No 14: Novel approaches to the diagnosis and classification of anti-FXIII allo-, and autoantibodies by László Muszbek, Hungary

17.50 – 18.00: Board No 15: High soluble thrombomodulin is associated with an increased risk for major bleeding during treatment with oral anticoagulants: a case-cohort study by Myrthe Toorop, The Netherlands

18.00 – 18.10: Board No 16: The effect of different prophylaxis regimens on fibrin gel structure in patients with severe hemophilia A by Irena Djunic, Serbia

18.10 – 18.20: Board No 17: Reduced clot firmness may contribute to bleeding phenotype in patients with mild bleeding disorders by Caroline Veen, The Netherlands

18.20 – 18.30: Board No 18: Genetics and hemostatic potential in hemophilia A patients with a discrepancy between one-stage and chromogenic assays: A cross-sectional study from Hemophilia centers in Stockholm and Belgrad by Annelie Stralfors, Sweden

Poster session – Bleeding 3

17.30 – 17.40: Board No 19: Sports participation and physical activity in patients with von Willebrand disease by Ferdows Atiq, The Netherlands

17.40 – 17.50: Board No 20: Platelet count and risk of major bleeding at venous thromboembolism diagnosis by Håkon Sandbukt Johnsen, Norway

17.50 – 18.00: Board No 21: Discrepancy between one-stage clotting and chromogenic substrate Factor IX assays in hemophilia B patients: A cross-sectional study from Stockholm hemophilia center by Maria Bruzelius, Sweden

18.00 – 18.10: Board No 22: A novel, cost effective lateral flow immunoassay (LFIA) technique for the diagnosis of severe von Willebrand disease (VWD) by Priyanka Kasatkar, India

18.10 – 18.20: Board No 23: Bleeding in subjects with congenital FXI deficiency exposed to risk situations: anticoagulant treatments and gynecological and obstetrical complications. Results from the real world by Carlos Bravo-Perez, Spain

18.20 – 18.30: Board No 24: Development of the first Point-of-Care Test selective of the direct oral anticoagulant Apixaban for emergency assessment of coagulation by Philippe Ohlmann, France

Poster session – Clotting 1

17.30 – 17.40: Board No 25: Prevalence and clinical features of a delayed or missed diagnosis of pulmonary embolism: A Swedish cross-sectional study from emergency department visits by Astrid Koorti Kroon, Sweden

17.40 – 17.50: Board No 26: Dietary intake of marine n-3 fatty acids is associated with lowered risk of incident by Trond Isaksen, Norway

17.50 – 18.00: Board No 27: Characterization of disease presentation and treatment outcomes in aTTP patients with initial or recurrent disease during the Phase III HERCULES trial of caplacizumab by Flora Peyvandi, Italy

18.00 – 18.10: Board No 28: Obese patients treated with apixaban and rivaroxaban for venous thromboembolism: a pilot study by Isabelle Gouin-Thibault, France

18.10 – 18.20: Board No 29: Red cell distribution width and risk of atrial fibrillation and subsequent thromboembolism. The Tromsø Study by Erin Mathiesen Hald, Norway

18.20 – 18.30: Board No 30: HIV infection and risk of recurrent venous thromboembolism: a community-based cohort study by James Francis Borjas Howard, The Netherlands

Poster session – Clotting  2

17.30 – 17.40: Board No 31: The Pseudonaja textilis factor Va A2 domain retains functional integrity following activated protein C-mediated proteolysis by Mark Schreuder, The Netherlands

17.40 – 17.50: Board No 32: A novel ADAMTS13 conformation ELISA shows conformational activation of rat ADAMTS13 with exposure of cryptic epitopes in vitro by Charlotte Dekimpe, Belgium

17.50 – 18.0o: Board No 33: Cytosolic localization of small antithrombins caused by a new mutation affecting the initiation codon in a large thrombophilic family. Bioinformatic analysis of mutations affecting initiation codons by María Eugenia de La Morena-Barrio, Spain

18.00 – 18.10: Board No 34: Mannose-binding lectin-associated serine protease-1 (MASP-1) of the complement system is associated with disseminated intravascular coagulation in septic shock patients by Julie Brogaard Larsen, Denmark

18.10 – 18.20: Board No 35: Anti-CUB1 or anti-spacer antibodies that increase ADAMTS13 activity act by allosterically enhancing metalloprotease domain function by An-Sofie Schelpe, Belgium

18.20 – 18.30: Board No 36: Structural features of acute ischemic stroke thrombi by Senna Staessens, Belgium

Poster session – Clotting 3

17.30 – 17.40: Board No 37: Phenotypic and genotypic analysis of a cohort of 114 patients with acquired thrombotic thrombocytopenic purpura by Nicolas Beranger, France

17.40 – 17.50: Board No 38: Cumulative meta-analysis of Low Molecular Weight Heparin’s antitumoral effect: toward the disappearance of the treatment effect by Edouard Ollier, France

17.50 – 18.00: Board No 39: Estimated cardiorespiratory fitness and future risk of venous thromboembolism in the general population by Line Holtet Evensen, Norway

18.00 – 18.10: Board No 40: Syncope Is Significant Predictor Of 30-day Mortality In Female Pulmonary Embolism Patients by Boris Dzudovic, Serbia

18.10 – 18.20: Board No 41: Pulmonary emboli localization – impact on clinical presentation and case fatality rate: A Swedish cross-sectional study from emergency department visits by Philip Smith, Sweden

18.20 – 18.30: Board No 42: Venous thromboembolism risk assessment in 936 women of reproductive age from families with thrombophilia: sub analysis of the MARFAST cohort by Pierre Suchon, France

Poster session – Clotting 4

17.30 – 17.40: Board No 43: Development of a prothrombinase-based assay to measure the susceptibility of factor V variants to inhibition by TFPIα by Peter van Doorn, The Netherlands

17.40 – 17.50: Board No 44: Clinical and laboratory characteristics of type IIHBS Antithrombin deficiency; prevalence of Antithrombin Budapest 3 mutation among different patients groups and investigation of its origin by Zsuzsanna Bereczky, Hungary

17.50 – 18.00: Board No 45: ABO blood group and venous thromboembolism risk: input of the measurements of plasmatic A and B glycosyltransferase activities by Manal Ibrahim-Kosta, France

18.00 – 18.10: Board No 46: Plasma miRNAs expression as markers for cardiovascular events in patients with atrial fibrillation by Constantino Martínez, Spain

18.10 – 18.20: Board No 47: Plasma levels of Procoagulant phospholipids (PPL) are associated with future risk of incident venous thromboembolism by Cathrine Ramberg, Norway

18.20 – 18.30: Board No 48: Measuring circulating FXIa to assess elevated FXIa as risk factor for thrombosis by Stan van der Beelen, The Netherlands

Poster session – Platelets 1

17.30 – 17.40: Board No 49: Immune thrombocytopenia (ITP) is associated with a high disease burden and has a negative impact on patient-reported quality of life and productivity: Results from the ITP World Impact Survey (I-WISh) by Nichola Cooper, United Kingdom

17.40 – 17.50: Board No 50: Hypersensitive platelet subpopulations determine collective behaviour: Results from a study of single platelet function using droplet microfluidics by Maaike Jongen, United Kingdom

17.50 – 18.00: Board No 51: Aspirin therapy reduces embolic events in patients with infective endocarditis by Laurence Camoin, France

18.00 – 18.10: Board No 52: Predictive factors for successful splenectomy outcome – systematic review by Mirjana Mitrovic, Serbia

18.10 – 18.20: Board No 53: Sticky Platelet Syndrome – epidemiological and clinical data from Slovak National Registry of Thrombophilia States by Jan Staško, Slovakia

18.20 – 18.30: Board No 54: Platelet aggregation varies by microenvironment in women with myeloproliferative neoplasms by Eugene Roitman, Russia

Poster session – Platelets 2

17.30 – 17.40: Board No 55: Immature platelet fraction (IPF): a surrogate marker of Mean Platelet Volume (MPV) in hereditary macrothrombocytopenia? By Anne Bauters, France

17.40 – 17.50: Board No 56: Flow cytometry-based platelet function testing for assessing platelet reactivity in inherited and acquired platelet dysfunction by Anastasia Ignatova, Russia

17.50 – 18.00: Board No 57: Disagregin: a platelet aggregation inhibitor from the tick Ornithodoros Moubata by Danique van den Kerkhof, The Netherlands

18.00 – 18.10: Board No 58: Platelet PN-1 regulates clot structure and retraction. By Yacine Boulaftali, France

18.10 – 18.20: Board No 59: Procoagulant activity of microparticles from stroke and mimics patients on endothelial cells by Véronique Ollivier, France

18.20 – 18.30: Board No 60: Is laboratory testing for Heparin-Induced Thrombocytopenia (HIT) requested after the use of 4Ts score system? A review. By Marcos Sousa, Portugal

19:15 - 00.00

Congress dinner
Les Grandes Tables at Friche La Belle de Mai (offsite)

The congress dinner of ECTH 2018 offers a great opportunity to meet and network with other experts in an informal setting, while tasting some local specialities from southern France. The walking dinner will take place in a unique space showcasing both industrial and contemporary aspects: Friche La Belle de Mai! At its restaurant, Les Grandes Tables, you will enjoy a variety of fresh seasonal products with a lively DJ setting the perfect atmosphere.

Buses will be arranged from the congress venue to the dinner location.
Price per person is €60 incl. VAT.  A ticket can be purchased via the registration website.